CytomX Therapeutics (CTMX) Stock Forecast & Price Target

Compare

877 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CTMX Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

CytomX

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CTMX Stock 12 Month Forecast

Average Price Target

$7.10

▲(61.73% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for CytomX Therapeutics in the last 3 months. The average price target is $7.10 with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 61.73% change from the last price of $4.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.729230769230769,5.168461538461538,5.607692307692307,6.046923076923077,6.4861538461538455,6.9253846153846155,7.364615384615385,7.803846153846154,8.243076923076924,8.682307692307692,9.12153846153846,9.560769230769232,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.506153846153846,4.722307692307692,4.938461538461539,5.154615384615385,5.3707692307692305,5.586923076923076,5.803076923076922,6.019230769230769,6.235384615384615,6.451538461538461,6.667692307692308,6.883846153846154,{"y":7.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.421538461538462,4.553076923076923,4.684615384615385,4.8161538461538465,4.947692307692308,5.07923076923077,5.21076923076923,5.342307692307692,5.473846153846154,5.605384615384615,5.736923076923077,5.868461538461538,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$7.10

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward Tenthoff

Piper Sandler

$6.5

Buy

48.06%

Upside

Reiterated

12/05/25

Piper Sandler Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)

Mitchell Kapoor

H.C. Wainwright

$10

Buy

127.79%

Upside

Reiterated

12/05/25

Buy Rating for CytomX Therapeutics' CX-2051 Based on Promising Colorectal Cancer Treatment PotentialValuation and Risks. Using a 25% probability of approval for CX-2051 in 3L colorectal cancer (CRC) along with a 12% discount rate and 1% terminal growth rate, our discounted cash flow (DCF)-based analysis yields a 12-month price objective of $10 per share assuming 204M fully-diluted shares as of end-2026. Risks include, but are not limited to: (1) trial delays; (2) failure to generate favorable clinical data, particularly with (3) possible long-term dilution risk. H.C. WAINWRIGHT & CO.

Olivia Brayer

Cantor Fitzgerald

Buy

36.67%

Upside

Reiterated

11/20/25

Cantor Fitzgerald Remains a Buy on CytomX Therapeutics (CTMX)

Etzer Darout

Barclays

Buy

36.67%

Upside

Reiterated

11/07/25

CytomX Therapeutics (CTMX) Receives a Buy from Barclays

Matthew Biegler

Oppenheimer

Buy

59.45%

Upside

Reiterated

11/06/25

Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL)

Anupam Rama

J.P. Morgan

―

Hold

―

Reiterated

10/27/25

Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$3.5

Buy

-20.27%

Downside

Initiated

09/17/25

CytomX Therapeutics (CTMX) Initiated with a Buy at Roth MKMCTMX Initiated Overweight w/$3.50 PT at Barclays

Robert Driscoll

Wedbush

Buy

36.67%

Upside

Reiterated

08/08/25

Joseph Catanzaro

Mizuho Securities

$3.25

Buy

-25.97%

Downside

Reiterated

03/07/25

Piper Sandler Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)

Soumit Roy

JonesTrading

Buy

59.45%

Upside

Reiterated

12/30/24

CytomX heading into 'major catalyst year,' says JonesResearchCytomX heading into 'major catalyst year,' says JonesResearch

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Tenthoff

Piper Sandler

$6.5

Buy

48.06%

Upside

Reiterated

12/05/25

Piper Sandler Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)

Mitchell Kapoor

H.C. Wainwright

$10

Buy

127.79%

Upside

Reiterated

12/05/25

Olivia Brayer

Cantor Fitzgerald

Buy

36.67%

Upside

Reiterated

11/20/25

Cantor Fitzgerald Remains a Buy on CytomX Therapeutics (CTMX)

Etzer Darout

Barclays

Buy

36.67%

Upside

Reiterated

11/07/25

CytomX Therapeutics (CTMX) Receives a Buy from Barclays

Matthew Biegler

Oppenheimer

Buy

59.45%

Upside

Reiterated

11/06/25

Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL)

Anupam Rama

J.P. Morgan

―

Hold

―

Reiterated

10/27/25

Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$3.5

Buy

-20.27%

Downside

Initiated

09/17/25

CytomX Therapeutics (CTMX) Initiated with a Buy at Roth MKMCTMX Initiated Overweight w/$3.50 PT at Barclays

Robert Driscoll

Wedbush

Buy

36.67%

Upside

Reiterated

08/08/25

Joseph Catanzaro

Mizuho Securities

$3.25

Buy

-25.97%

Downside

Reiterated

03/07/25

Piper Sandler Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)

Soumit Roy

JonesTrading

Buy

59.45%

Upside

Reiterated

12/30/24

CytomX heading into 'major catalyst year,' says JonesResearchCytomX heading into 'major catalyst year,' says JonesResearch

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CytomX Therapeutics

1 Month

xxx

Success Rate

7/10 ratings generated profit

Average Return

+18.27%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +18.27% per trade.

3 Months

xxx

Success Rate

8/10 ratings generated profit

Average Return

+15.57%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +15.57% per trade.

1 Year

Etzer DaroutBarclays

Success Rate

6/10 ratings generated profit

Average Return

+7.78%

reiterated a buy rating 2 months ago

Copying Etzer Darout's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +7.78% per trade.

2 Years

xxx

Success Rate

6/10 ratings generated profit

Average Return

+7.78%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +7.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CTMX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CTMX has received 12 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. CTMX average Analyst price target in the past 3 months is 7.10.

Each month's total comprises the sum of three months' worth of ratings.

CTMX Financial Forecast

CTMX Earnings Forecast

Next quarter’s earnings estimate for CTMX is -$0.09 with a range of -$0.17 to -$0.03. The previous quarter’s EPS was -$0.09. CTMX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CTMX has Performed in-line its overall industry.

CTMX Sales Forecast

Next quarter’s sales forecast for CTMX is $7.55M with a range of $4.00M to $15.00M. The previous quarter’s sales results were $5.96M. CTMX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CTMX has Performed in-line its overall industry.

CTMX Stock Forecast FAQ

What is CTMX’s average 12-month price target, according to analysts?

Based on analyst ratings, CytomX Therapeutics Inc’s 12-month average price target is 7.10.

What is CTMX’s upside potential, based on the analysts’ average price target?

CytomX Therapeutics Inc has 61.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CTMX a Buy, Sell or Hold?

CytomX Therapeutics Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is CytomX Therapeutics Inc’s price target?

The average price target for CytomX Therapeutics Inc is 7.10. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 61.73% Increase from the current price of $4.39.

What do analysts say about CytomX Therapeutics Inc?

CytomX Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of CTMX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

CytomX Therapeutics (CTMX) Stock Forecast & Price Target

CTMX Analyst Ratings

CTMX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CytomX Therapeutics

CTMX Analyst Recommendation Trends

CTMX Financial Forecast

CTMX Earnings Forecast

CTMX Sales Forecast

CTMX Stock Forecast FAQ

Detailed List of Analyst Forecasts